Penumbra, Inc Research and Development in Process
Penumbra, Inc (PEN) reported Research and Development in Process of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2021-02-23
- Penumbra, Inc research and development in process for fiscal 2020 was $0.00.
- Penumbra, Inc research and development in process for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Penumbra, Inc research and development in process for fiscal 2018 was $30.84M.
- Penumbra, Inc research and development in process for fiscal 2017 was $0.00.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-23 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-23 |
| 2018-12-31 | $30.84M 10-K · filed 2021-02-23 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |